Navigation Links
Clostridium difficile Infection: Current Challenges and Controversies
Date:1/20/2009

Complimentary Continuing Education Virtual Lecture and Podcast for Healthcare Professionals

VOORHEES, N.J., Jan. 20 /PRNewswire/ -- Current education about Clostridium difficile infection (CDI) is critical for several reasons. The epidemiology of CDI is changing and has been marked by increasing rates and more severe disease. In addition, the epidemic strain continues to be reported in an expanding list of states across the United States and worldwide.

To address the need for current education on CDI risk factors, diagnostic techniques, and optimal treatment strategies, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture and podcast for physicians, pharmacists, and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from ViroPharma Incorporated.

The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/IDSA Joint Meeting. The chairperson for this program is international expert in infectious diseases, Dale N. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Associate Chief of Staff for Research and Development at Hines Veterans Affairs Hospital in Hines, Illinois. Other faculty include experts in infectious diseases, gastroenterology, and infection control from leading medical institutions across the United States.

Healthcare professionals can visit www.rmei.com/CDI052 to access this virtual lecture and podcast.

"Robert Michael Educational Institute LLC recognizes that continuing education plays a crucial role
'/>"/>

SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Putting a new spin on current research
3. New small-scale generator produces alternating current by stretching zinc oxide wires
4. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
5. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
6. 72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
7. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
8. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
9. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... of molecular diagnostic test results. It also enables ... for the validation and reporting of high profile ... diagnostics is a rapidly growing area of biotechnology ... genetic predisposition, cancer, and companion diagnostics in personalized ...
(Date:7/23/2014)... 23, 2014  Sangamo BioSciences, Inc. (NASDAQ: ... results and accomplishments. For the second ... net loss of $7.0 million, or $0.10 per share, ... $0.10 per share, for the same period in 2013. ... cash equivalents, marketable securities and interest receivable of $236.7 ...
(Date:7/23/2014)... the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University of ... succeeded in embedding nearly perfect semiconductor crystals into ... producing hybrid nanowires, very fast and multi-functional processing ... in the future. The research results will be ... , Nano-optoelectronics are considered the cornerstone of future ...
(Date:7/23/2014)... 23, 2014 Shimadzu Scientific Instruments ... acid analysis system developed jointly with Ajinomoto Co. ... can analyze 38 amino acids in nine minutes, ... achieves high-speed analysis utilizing a fast application-specific column ... accurate analytical results even under conditions with difficult ...
Breaking Biology Technology:New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2
... SAN DIEGO, CA, July 30, 2009 Senomyx, Inc. (Nasdaq: ... on Tuesday, August 4, 2009 before the opening of the U.S. financial ... Internet broadcast that will provide a corporate update and a review of ... Time (8:00 a.m. Pacific Time). , , To participate ...
... , , ALPHARETTA, Ga., July ... announced the appointment of Philip Vogt as Executive Vice President, ... more than thirty years of pharmaceutical experience and will ... to this role, Vogt served as President of Ethex Corporation ...
... SOUTH SAN FRANCISCO, Calif., July 30 Sunesis Pharmaceuticals, ... on the development and commercialization of new oncology therapeutics for ... NASDAQ has approved its application to transfer the listing of ... NASDAQ Capital Market. The transfer will be effective at the ...
Cached Biology Technology:SENOMYX, INC. SECOND QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 4, 2009 2Sunesis Receives Approval for Listing on The NASDAQ Capital Market 2Sunesis Receives Approval for Listing on The NASDAQ Capital Market 3
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... tomorrow (14 October) as CSIRO launches in the United ... 2006 in Atlanta, Georgia, the world's largest conference for ... mathematical method, patented by Australia's CSIRO, for automatically tracing ... With up to 40,000 delegates expected, the conference will ...
... for treating a recurrent cancer of the central nervous ... glioma, has shown promising results in preliminary data from ... from the first group of six patients in the ... Center, showed that vitespen (trademarked as Oncophage), a vaccine ...
... a few dozen trillions, a human adult has about 70 ... 959 cells. , Yet we have an awful lot ... been exploring two “highly conserved? cell-signaling pathways for innate immunity ... a lot of common enemies, particularly soil-borne pathogens. C. elegans, ...
Cached Biology News:Vaccine for brain tumors shows promising results 2Vaccine for brain tumors shows promising results 3Worms produce surprise insight into human fever 2
... polyclonal to ThPok ( Abpromise for all ... peptide conjugated to KLH derived from within residues ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Pronase Reagent...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: